Cargando…
Syngeneic leukemia models using lentiviral transgenics
Animal models are necessary to study cancer and develop treatments. After decades of intensive research, effective treatments are available for only a few types of leukemia, while others are currently incurable. Our goal was to generate novel leukemia models in immunocompetent mice. We had achieved...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893004/ https://www.ncbi.nlm.nih.gov/pubmed/33602907 http://dx.doi.org/10.1038/s41419-021-03477-2 |
_version_ | 1783652972779012096 |
---|---|
author | Keinan, Nurit Scharff, Ye’ela Goldstein, Oron Chamo, Michael Ilic, Stefan Gazit, Roi |
author_facet | Keinan, Nurit Scharff, Ye’ela Goldstein, Oron Chamo, Michael Ilic, Stefan Gazit, Roi |
author_sort | Keinan, Nurit |
collection | PubMed |
description | Animal models are necessary to study cancer and develop treatments. After decades of intensive research, effective treatments are available for only a few types of leukemia, while others are currently incurable. Our goal was to generate novel leukemia models in immunocompetent mice. We had achieved abilities for overexpression of multiple driving oncogenes simultaneously in normal primary cells, which can be transplanted and followed in vivo. Our experiments demonstrated the induction of primary malignant growth. Leukemia lines that model various types of leukemia, such as acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL), were passaged robustly in congenic wild-type immunocompetent mice. These novel leukemia lines, which may complement previous models, offer the flexibility to generate tailored models of defined oncogenes of interest. The characterization of our leukemia models in immunocompetent animals can uncover the mechanisms of malignancy progression and offer a unique opportunity to stringently test anti-cancer chemotherapies. |
format | Online Article Text |
id | pubmed-7893004 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-78930042021-03-03 Syngeneic leukemia models using lentiviral transgenics Keinan, Nurit Scharff, Ye’ela Goldstein, Oron Chamo, Michael Ilic, Stefan Gazit, Roi Cell Death Dis Article Animal models are necessary to study cancer and develop treatments. After decades of intensive research, effective treatments are available for only a few types of leukemia, while others are currently incurable. Our goal was to generate novel leukemia models in immunocompetent mice. We had achieved abilities for overexpression of multiple driving oncogenes simultaneously in normal primary cells, which can be transplanted and followed in vivo. Our experiments demonstrated the induction of primary malignant growth. Leukemia lines that model various types of leukemia, such as acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL), were passaged robustly in congenic wild-type immunocompetent mice. These novel leukemia lines, which may complement previous models, offer the flexibility to generate tailored models of defined oncogenes of interest. The characterization of our leukemia models in immunocompetent animals can uncover the mechanisms of malignancy progression and offer a unique opportunity to stringently test anti-cancer chemotherapies. Nature Publishing Group UK 2021-02-18 /pmc/articles/PMC7893004/ /pubmed/33602907 http://dx.doi.org/10.1038/s41419-021-03477-2 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Keinan, Nurit Scharff, Ye’ela Goldstein, Oron Chamo, Michael Ilic, Stefan Gazit, Roi Syngeneic leukemia models using lentiviral transgenics |
title | Syngeneic leukemia models using lentiviral transgenics |
title_full | Syngeneic leukemia models using lentiviral transgenics |
title_fullStr | Syngeneic leukemia models using lentiviral transgenics |
title_full_unstemmed | Syngeneic leukemia models using lentiviral transgenics |
title_short | Syngeneic leukemia models using lentiviral transgenics |
title_sort | syngeneic leukemia models using lentiviral transgenics |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893004/ https://www.ncbi.nlm.nih.gov/pubmed/33602907 http://dx.doi.org/10.1038/s41419-021-03477-2 |
work_keys_str_mv | AT keinannurit syngeneicleukemiamodelsusinglentiviraltransgenics AT scharffyeela syngeneicleukemiamodelsusinglentiviraltransgenics AT goldsteinoron syngeneicleukemiamodelsusinglentiviraltransgenics AT chamomichael syngeneicleukemiamodelsusinglentiviraltransgenics AT ilicstefan syngeneicleukemiamodelsusinglentiviraltransgenics AT gazitroi syngeneicleukemiamodelsusinglentiviraltransgenics |